AHA Scientific Sessions 2026 AbstractNov 9, 2026, 00:44 GMT

Enicepatide linked to lower abdominal fat markers across ages

At 48 weeks, waist circumference fell 11.6%, 12.4% and 14.3% at increasing enicepatide doses, compared with 1.5% with placebo.

Paper by Nikolaus Marx, Javed Butler, Helen Colhoun, +4Odd Erik Johansen · Univ Hosp Aachen · Roche

Our read

Interventions

Studied:: Randomized trial in 467 adults with obesity or overweight, 48 weeks, against placebo (Double-blind, placebo-controlled, dose-response, registered NCT06525935)
What changed:: Waist circumference fell 11.6%, 12.4% and 14.3% with enicepatide, compared with 1.5% with placebo
The catch:: The age comparisons were an exploratory, after-the-fact subgroup analysis
In the record:: One of 5 papers on CT-388 on record: 4 with results in people.

Editor of record: Boris Djordjevic · AgingResearch.News

Paper

The 467 women and men in this randomized, placebo-controlled trial had obesity or overweight and at least one weight-related condition; 65 were aged 65 or older. An exploratory analysis compared weekly injections of enicepatide, gradually increased to 8, 16 or 24 milligrams, with placebo.

At 48 weeks, treatment was associated with dose-dependent reductions in waist circumference and other measures used to predict cardiovascular risk from abdominal fat. Reductions were evident by 12 weeks. Waist circumference fell 11.6%, 12.4% and 14.3% at the respective doses, compared with 1.5% with placebo. Changes were largely consistent across age groups, although the reduction in a blood marker reflecting fat around internal organs was smaller in older adults.

Why it matters

For older and younger adults with obesity or overweight, these changes may translate into cardiovascular benefits, the authors suggested.

Caveats

The exploratory, after-the-fact analysis assessed risk markers rather than cardiovascular events. Only 65 trial participants were 65 or older, including 10 assigned placebo; the conference abstract did not report side effects.